LOVFF (Cannara Biotech) Accounts Payable: $8.73 Mil (As of Feb. 2026)


LOVFF Cannara Biotech Inc LOVFF
85 GF Score
Price $1.29
GF Value $1.17
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Cannara Biotech Accounts Payable?

Cannara Biotech LOVFF +0.62% 85 Accounts Payable is $8.73 Mil as of Feb. 2026. GuruFocus rates LOVFF with a GF Score™ of 85/100 and a GF Value™ of $1.17 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Cannara Biotech's Accounts Payable for the quarter that ended in Feb. 2026 was $8.73 Mil.

Cannara Biotech's quarterly Accounts Payable increased from Aug. 2025 ($8.03 Mil) to Nov. 2025 ($8.69 Mil) and increased from Nov. 2025 ($8.69 Mil) to Feb. 2026 ($8.73 Mil).

Cannara Biotech's annual Accounts Payable increased from Aug. 2023 ($6.59 Mil) to Aug. 2024 ($7.21 Mil) and increased from Aug. 2024 ($7.21 Mil) to Aug. 2025 ($8.03 Mil).

Cannara Biotech Accounts Payable Related Terms

Cannara Biotech Accounts Payable Historical Data

* Premium members only.

The historical data trend for Cannara Biotech's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannara Biotech Accounts Payable Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Accounts Payable
Get a 7-Day Free Trial 4.97 7.21 6.59 7.21 8.03

Cannara Biotech Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.05 8.86 8.03 8.69 8.73
LOVFF
85GF Score
Cannara Biotech Inc LOVFF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cannara Biotech Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $8.73 Mil mean?
Cannara Biotech (LOVFF) has a Accounts Payable of $8.73 Mil as of Feb. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Cannara Biotech and its competitors.
Is Cannara Biotech's Accounts Payable too high?
Cannara Biotech's current Accounts Payable is $8.73 Mil. Overall, Cannara Biotech has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Accounts Payable compare to ZTS and UTHR?
Cannara Biotech's Accounts Payable of $8.73 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Cannara Biotech and its competitors. Cannara Biotech's current Accounts Payable is $8.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.17, compared to a current price of $1.29 — trading 10.6% above its estimated fair value. The current Accounts Payable is $8.73 Mil. Cannara Biotech's overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Accounts Payable is $8.73 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cannara Biotech (LOVFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued. The current stock price of $1.29 is trading 10.6% above its estimated GF Value™ of $1.17. GuruFocus considers Cannara Biotech to be Modestly Overvalued.

Key valuation signals for LOVFF:

  • Accounts Payable: $8.73 Mil
  • GF Value™: $1.17 vs. price of $1.29 (10.6% above fair value)
  • GF Score™: 85/100 with 5 warning signs

No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cannara Biotech Business Description

Other Exchanges 8CB0:GermanyLOVE:Canada
Address 1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
85GF Score

Get the complete analysis for LOVFF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.29
Price
$1.17
GF Value